Amalgamated Bank Has $133,000 Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Amalgamated Bank increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 55.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,566 shares of the company’s stock after acquiring an additional 2,354 shares during the quarter. Amalgamated Bank’s holdings in Hims & Hers Health were worth $133,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the period. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares in the last quarter. M&G Plc acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at $8,232,000. State of Michigan Retirement System grew its holdings in shares of Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after acquiring an additional 320,000 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after acquiring an additional 273,473 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $19.32 on Wednesday. The firm has a fifty day moving average of $16.82 and a 200-day moving average of $17.25. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -1,931.50 and a beta of 1.05. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company’s revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.03) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $551,777.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 542,585 shares of company stock valued at $8,751,851. 17.71% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HIMS shares. Piper Sandler reissued a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. TD Cowen upped their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Truist Financial raised their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.